[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hipec\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hipec":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,84,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100629727","impact-of-an-omega-3-enriched-oral-nutritional-supplement-on-improving-surgical-outcomes-in-patients-with-peritoneal-carcinomatosis-undergoing-cytoreductive-surgery-100629727",false,"NCT07478432","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery","Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery: A Pilot, Prospective, Randomized, Double-Blind, Controlled Study","OMNI","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of peritoneal carcinomatosis from a non-gynecological primary neoplasm\n* Patients who must undergo cytoreductive surgery and HIPEC\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Patients with an enterocutaneous fistula\n* Patients with known food allergies\n* Age \\\u003C 18 years\n* Patients with severe organ damage (e.g., kidney failure, liver failure)\n* Refusal to sign the informed consent form","ALL","18 Years",{"count":20,"type":21},28,"ESTIMATED","INTERVENTIONAL",[24],"NA","The OMNI study is a clinical trial investigating whether a nutritional supplement with added Omega-3 fatty acids can improve surgical outcomes for patients with peritoneal carcinomatosis. Peritoneal carcinomatosis is a type of cancer that affects the abdominal lining and often requires complex and extensive surgery called cytoreductive surgery (CRS). This procedure is associated with a high risk of postoperative complications, such as infections and long hospital stays. Omega-3 fatty acids are known for their anti-inflammatory and immune-modulating properties.\n\nThe study's main goal is to see if a 21-day regimen of a pre-operative Omega-3 enriched oral nutritional supplement (ONS) can reduce postoperative complications, as measured by the Clavien-Dindo classification.\n\nWho can participate?\n\nThe study is recruiting patients over 18 years old who have been diagnosed with non-gynecological peritoneal carcinomatosis and are scheduled to undergo cytoreductive surgery and HIPEC (hyperthermic intraperitoneal chemotherapy).\n\nWhat does participating involve?\n\nUpon joining the study, participants will be randomly assigned to one of two groups:\n\n* Intervention Group: Participants will receive an Omega-3 enriched nutritional supplement called Fortimel Forticare.\n* Control Group: Participants will receive a standard nutritional supplement called Fortimel Compact Protein.\n\nBoth groups will be asked to consume two bottles of their assigned supplement per day for 21 days before the scheduled surgery.\n\nWhat will be measured?\n\nThroughout the study, the investigators will perform various assessments to monitor participant health and recovery:\n\n* Before and after surgery: The investigators will take body measurements, conduct a bioimpedance analysis (BIA) to check body composition, and perform a Hand Grip test to measure muscle strength. The investigators will also collect blood and stool samples.\n* During surgery: The investigators will collect tissue samples to study the tumor environment.\n* After surgery: The investigators will track patient recovery, including the length of the hospital stay and any complications that may occur. The investigators will also continue to monitor certain markers in the patients' blood.\n\nThe study is expected to enroll a total of 28 patients.",[27,28,29,30],"Peritoneal Carcinosis","Peritoneal Metastases","HIPEC","Cytoreductive Surgery","NOT_YET_RECRUITING","2026-03-13",{"date":34,"type":35},"2026-03-17","ACTUAL",{"date":37,"type":21},"2026-04",{"date":39,"type":21},"2028-10",{"name":41,"class":42},"Catholic University of the Sacred Heart","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":43},"100617050","hyperthermic-intraperitoneal-chemoperfusion-hipec-in-gastric-cancer-100617050","NCT07313579","Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","Observational Prospective Cohort Study on Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer","G-PEC","Inclusion Criteria:\n\n1. Age 18-80\n2. Hystologicaly proven gastric adenocarcinoma\n3. ECOG status 0-1\n4. Written consent to participate in the study\n5. Medically and technically operable gastric tumor\n6. Only T4a or T4b tumours with any peritoneal cytology status\n7. Cytologically positive peritoneal washings (cyt+) with any T and N criteria\n8. Adequate haemopoetic, renal and hepatic function (Hb \\> 120, PLT \\> 150\\*10\\^9\u002Fl, ALT \\\u003C 60, AST \\\u003C40, total bilirubin \\\u003C 21 µmol\u002Fl, Creatinine clearance (male - 90-140, female - 80-130 ml\u002Fmin)\n\nExclusion Criteria:\n\n1. Pregnancy\u002Fbreastfeeding\n2. ECOG status 2-4\n3. Concomitant malignancy\n4. Mitomycin and\u002For Cisplatin hypersensitivity\n5. Uncontrollable chronic diseases\n6. Patients with coexisting malignancy other than basal cell carcinoma of the skin within the last five years.\n7. Presence of metastases other than regional or peritoneal (such as liver, lungs, bone, brain, distant lymph nodes)\n8. History of allergic reactions associated with cisplatin and Mitomycin C\n9. Patients with psychiatric illness\u002Fsocial situations with impaired compliance\n10. •Refusal to participate","80 Years",{"count":54,"type":21},200,"OBSERVATIONAL","The study investigates the outcomes of hyperthermic intraperitoneal chemoperfusion (HIPEC) in combination with curative-intent gastrectomy in resectable locally-advanced and limited-metastatic (low peritoneal cancer index) gastric cancer.",[58,29,59,60],"Gastric Cancer (GC)","Peritoneal Metastases From Gastric Cancer","Hyperthermic Intraperitoneal Chemoperfusion",[62,29,60,63,64,65,66,67,68,69,70,71,72,73],"Gastric cancer","FLOT","Lymphadenectomy","Gastrointestinal Neoplasms","Digestive System Neoplasms","Gastrointestinal Diseases","Stomach Diseases","Stomach Neoplasms","Chemotherapy, Adjuvant","Combined Modality Therapy","Drug Therapy","Surgical Procedures","RECRUITING","2026-01-10",{"date":77,"type":35},"2026-01-13",{"date":79,"type":35},"2025-12-01",{"date":81,"type":21},"2035-12-01",{"name":83,"class":42},"Ukrainian Society of Clinical Oncology",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":29,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":43},"100472057","thermodynamic-model-of-hyperthermia-in-humans-undergoing-hipec-100472057","NCT05426928","Thermodynamic Model of Hyperthermia in Humans Undergoing HIPEC","Development of a Computational, Thermodynamic Model of Intraabdominal Hyperthermia in Humans Undergoing HIPEC","Inclusion Criteria:\n\n* Adults (at least 18 years or older)\n* Scheduled to undergo HIPEC surgery for abdominal cancer at HFH-Main\n\nExclusion Criteria:\n\n* Pregnant females\n* Minors\n* Disease not amenable for treatment with HIPEC after surgical examination.",{"count":92,"type":21},30,"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a well-established alternative for patients with peritoneal surface malignancies. Although HIPEC has a predetermined protocol to manage body temperature, the resultant bladder and core-body temperatures are highly variable and unstable in clinical practice. Such results highlight an incomplete understanding of the thermodynamic processes during HIPEC in humans.\n\nPrevious clinical and animal investigations have studied abdominal hyperthermia, but a full human model incorporating patient variables, heat delivery, and the impact of the circulatory system and anesthesia in HIPEC has not been established.\n\nThis project seeks to develop and validate a computational thermodynamic model using prospective real-world data from humans undergoing HIPEC surgery. It is hypothesized that by incorporating patient, anesthetic, and perfusion-related variables in a thermodynamic model, the temperatures inside and outside the abdomen during HIPEC can be predicted.",[29],[96,97,98],"Predictive model","Intraabdominal hyperthermia","Thermodynamics","2025-10-15",{"date":101,"type":35},"2025-10-20",{"date":103,"type":35},"2022-09-22",{"date":105,"type":21},"2027-03-31",{"name":107,"class":42},"Henry Ford Health System",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":115,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":43},"100598183","phase-2-evaluating-the-efficacy-of-hyperthermic-intraperitoneal-treatment-to-enhance-the-sensitivity-of-immune-checkpoint-inhibitor-in-patients-with-advanced-ovarian-cancer-a-single-arm-study-100598183","NCT07068178","Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study","ICI-HIPET","Inclusion Criteria:\n\n* Diagnosed with FIGO stage IIIC-IVA high-grade serous ovarian adenocarcinoma (histologically confirmed).\n* Aged 18-70 years.\n* Life expectancy ≥12 months.\n* CT Suidan score ≥7 and Fagotti score ≥8 (assessed by two independent gynecologic oncologists via laparoscopic evaluation).\n* Adequate organ function:AST\u002FALT ≤2× upper limit of normal (ULN);Total bilirubin ≤1.5× ULN;Serum creatinine ≤1.5× ULN.\n* No myelosuppression:Hemoglobin (Hb) ≥80 g\u002FL,White blood cell count (WBC) ≥2.0×10⁹\u002FL,Neutrophil count ≥1.0×10⁹\u002FL,Platelet count ≥100×10⁹\u002FL.\n* Performance Status (PS) score 0-1.\n\nExclusion Criteria:(Excluded if any criterion is met)\n\n* Partial or complete bowel obstruction.\n* Intestinal fistula of any grade.\n* Hydronephrosis unrelieved by ureteral stenting.\n* History of organ transplantation.\n* Inflammatory bowel disease.\n* Active or history of autoimmune diseases (e.g., systemic lupus erythematosus).\n* Prior immunotherapy (including cellular therapy) or use of immunomodulators.\n* Brain metastases.\n* Grade ≥3 venous thromboembolism.\n* Active infections (e.g., tuberculosis).\n* Prior pelvic\u002Fabdominal radiotherapy.\n* Prior hyperthermic intraperitoneal chemotherapy (HIPEC) or thermotherapy.\n* Grade ≥2 dysfunction of major organs (e.g., heart, liver, kidneys).\n* Other malignancies within 5 years (except skin or thyroid cancer).\n* Psychiatric disorders affecting compliance.","FEMALE","70 Years",{"count":92,"type":21},[119],"PHASE2","Background:\n\nAdvanced ovarian cancer is a highly dangerous disease, and many patients lose their lives due to limited treatment effectiveness. Previous studies have shown that current immunotherapy (e.g., PD-1 inhibitors) has poor results in ovarian cancer. The research team discovered that adding \"heated abdominal chemotherapy\" (called HIPEC, which uses a heated drug solution to wash the abdomen) to standard chemotherapy helps patients better control tumors. Recent lab studies also found that HIPEC not only reduces \"harmful cells\" around tumors that block drug effectiveness but also makes immunotherapy drugs work better. Animal experiments further confirmed that combining HIPEC with immunotherapy improves outcomes. Therefore, the investigators aim to test a key question: Can HIPEC help immunotherapy drugs work more effectively in humans?\n\nStudy Details:\n\nThe study will conduct a small two-phase trial, planning to enroll 30 patients with advanced ovarian cancer (Stage IIIc-IVA). All participants will receive standard chemotherapy (paclitaxel + platinum drugs) combined with HIPEC and an immunotherapy drug (tislelizumab, a PD-1 inhibitor). The main goal is to check whether tumors are completely removed after surgery. Investigators will also track how long tumors stay under control, overall survival time, treatment safety, and use blood and tumor tissue tests to find biomarkers that predict treatment response.\n\nWhy This Matters:\n\nThe study hopes to identify a safe method to enhance immunotherapy effectiveness and offer improved outcomes for advanced ovarian cancer patients.",[29,122],"Ovarian Serous Adenocarcinoma",[113],"2025-07-06",{"date":126,"type":35},"2025-07-16",{"date":128,"type":21},"2025-08",{"date":130,"type":21},"2030-01",{"name":132,"class":42},"Jing Li"]